1988 Volume 29 Issue 11 Pages 2042-2047
Crosslinked fibrin degradation products (XDP) have been considered to be specific markers for differential diagnosis between DIC and fibrinogenolysis. In the present study, we quantitatively assayed the levels of XDP in normal subjects and patients with DIC and several other diseases by a newly developed assay procedure (particle counting immunoassay) based on the agglutination of latex particles coated with monoclonal antibodies. We then determined the usefulness of this assay procedure. The within-run and between-day reproducibilities of this method were satisfactory and the levels of XDP in plasma samples were closely correlated with those in serum samples obtained from the same patients. Comparing this method with previously established method, a good correlation was noted between these methods. The concentrations of XDP in many of normal subjects were less than 0.3 μg/ml, but moderately elevated XDP values occurred in some of 80 year old healthy subjects. In cases of DIC including patients with acute promyelocytic leukemia, the levels of XDP were markedly elevated. Mederate or slight elevation of XDP was seen in some cases of chronic cerebrovascular disorders, malignancy or diabetes mellitus. It was suggested that this assay procedure has a good reproducibility, is very simple and taken little times to diagnose DIC.
